Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Lawson Health Research Institute QLT Inc Canadian Retinal Trials Group |
---|---|
Information provided by: | Lawson Health Research Institute |
ClinicalTrials.gov Identifier: | NCT00376701 |
The primary purpose of the study is to investigate whether patients with Choroidal Neovascularization secondary to Age-related Macular Degeneration, receiving triple or double therapy compared to monotherapy with Avastin will reduce the intervention rate with equivalent safety and efficacy.
Condition | Intervention | Phase |
---|---|---|
Age Related Macular Degeneration |
Drug: Avastin (Bevacizumab) Drug: Bevacizumab |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Factorial Assignment, Safety/Efficacy Study |
Official Title: | Combination Therapy in Neovascular Age-Related Macular Degeneration (AMD): A Three-Armed, Randomized, Prospective Clinical Trial of Low Fluence Photodynamic Therapy(rPDT) With Adjunctive Avastin and Triamcinolone Acetonide (Kenalog)(Triple Therapy) Versus rPDT With Adjunctive Avastin (Double Therapy) Versus Monotherapy With Avastin. |
Enrollment: | 106 |
Study Start Date: | September 2006 |
Estimated Study Completion Date: | April 2009 |
Primary Completion Date: | April 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
Reduced fluence PDT plus intravitreal Kenalog (2 mg) plus intravitreal Avastin 1.25 mg
|
Drug: Avastin (Bevacizumab)
Avastin 1.25 mg intravitreal
Drug: Bevacizumab
Intrarvitreal 1.25 mg
|
2: Experimental
Reduced fluence PDT plus intravitreal Avastin
|
Drug: Avastin (Bevacizumab)
Avastin 1.25 mg intravitreal
Drug: Bevacizumab
Intravitreal 1.25 mg
|
3: Experimental
Intravitreal Avastin and sham reduced fluence PDT
|
Drug: Avastin (Bevacizumab)
Avastin 1.25 mg intravitreal
Drug: Bevacizumab
Intravitreal Avastin 1.25 mg and sham reduced fluence PDT
|
Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in developed countries throughout the world.The beneficial therapeutic effect of Photodynamic Therapy (PDT)in the treatment of AMD is modest. The treatment benefit of PDT may be moderated by PDT-induced, non-selective effects in the choroidal circulation (resulting in hypoxia-induced stimulation of angiogenesis through increased vascular endothelial growth factor (VEGF)production), direct injury to the retinal pigment epithelium, and subretinal fluid/hemorrhage or post-treatment inflammation secondary to PDT. There is potential that supplemental Avastin (through VEGF inhibition) or intravitreal Triamcinolone Acetonide (ITA) treatments (through non-specific membrane stabilizing, anti-neovascular, and anti-inflammatory activities) could minimize the effect of these processes, enhancing the efficacy of PDT. Presently, PDT, the current gold standard,in combination with Avastin and/or Kenalog is being more widely used in exactly this fashion and may become the standard of care without the necessary randomized clinical trial. However, the treatment benefit of these interventions is uncertain as is their safety profile.
This randomized, controlled trial addresses the potential supplemental therapeutic effect of intravitreal injection of Triamcinolone Acetonide and/or Avastin in conjunction with photodynamic therapy for the treatment of sub-foveal CNVM secondary to AMD.
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Canada, Alberta | |
The University of Alberta and Capital Health | |
Edmonton, Alberta, Canada, T5H 3V9 | |
Canada, British Columbia | |
The University of British Columbia | |
Vancouver, British Columbia, Canada, V5Z 3N9 | |
Dr. Stanley G. Shortt | |
Victoria, British Columbia, Canada, V8V 4X3 | |
Canada, Ontario | |
Ivey Eye Institute, St. Joseph's Health Care Centre | |
London, Ontario, Canada, N6A 4G5 | |
Sunnybrook Health Sciences Centre | |
Toronto, Ontario, Canada, M4M 3M5 |
Principal Investigator: | Thomas G. Sheidow, MD | University of Western Ontario, Canada |
Responsible Party: | Ivey Eye Institute, London, Ontario, Canada ( DR. Tom Sheidow ) |
Study ID Numbers: | R-06-441, Health Canada Control #106990, 9427-U0207/2-21C |
Study First Received: | September 14, 2006 |
Last Updated: | August 14, 2008 |
ClinicalTrials.gov Identifier: | NCT00376701 |
Health Authority: | Canada: Health Canada |
Choroidal Neovascularization Photodynamic Therapy Age Related Macular Degeneration |
Triamcinolone Acetonide Avastin Visudyne |
Eye Diseases Verteporfin Macular Degeneration Retinal Degeneration Triamcinolone diacetate Bevacizumab Choroidal Neovascularization |
Triamcinolone hexacetonide Triamcinolone Acetonide Triamcinolone Neovascularization, Pathologic Retinal Diseases Retinal degeneration |
Anti-Inflammatory Agents Immunologic Factors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Growth Substances Physiological Effects of Drugs Hormones, Hormone Substitutes, and Hormone Antagonists Enzyme Inhibitors |
Glucocorticoids Hormones Immunosuppressive Agents Angiogenesis Inhibitors Pharmacologic Actions Therapeutic Uses Growth Inhibitors Angiogenesis Modulating Agents |